Hormone replacement therapy (HRT) is often discussed as a single, universal fix for menopause. The evidence does not support that view. How well HRT works depends heavily on which symptom is being treated.
October 2026 brought a meaningful shift. The American College of Obstetricians and Gynecologists (ACOG) published Clinical Practice Guideline No. 13 on October 15, 2026, its first update since 2014. The American College of Physicians (ACP) released a parallel framework that sorts treatments into first-line, second-line, and third-line options.
This article does not survey every menopause medication. It maps where HRT itself is strongly supported, conditionally supported, or not supported across five symptom clusters: vasomotor symptoms, VMS-related sleep disturbance, vaginal and urinary symptoms, mood, and libido. Timing, often called the “window of opportunity,” matters as much as symptom type, and the article returns to it at the end.
Why the Blanket-Fix Framing Doesn’t Hold Up
About 80% of women experience menopause symptoms. Yet only 4% to 6% of U.S. women are currently prescribed HRT, down from roughly 27% at the pre-WHI peak in 2000. The new guidelines aim to close that gap, and closing it responsibly requires clarity about which symptoms have strong evidence behind them.
Symptoms also vary widely. According to ACOG, 50% to 92% of women report vasomotor symptoms (VMS), 16% to 66% report sleep issues, and more than one-third report depressive symptoms during the transition. Such wide variation makes a one-size-fits-all answer clinically imprecise. The sections below grade the evidence symptom by symptom rather than grading HRT as a whole.
The 2026 Guideline Landscape: Two Frameworks, One Direction
ACOG Clinical Practice Guideline No. 13 strongly recommends systemic hormone therapy for vasomotor symptoms and VMS-related sleep disturbance in eligible patients.
ACP’s October 2026 recommendation names estrogen (with a progestogen if the uterus is intact) as first-line treatment for hot flashes and night sweats. SNRIs such as venlafaxine are second-line. SSRIs, gabapentin, or neurokinin receptor antagonists are third-line.
The two frameworks reinforce each other. ACOG grades the strength of the evidence, and ACP sequences the clinical decisions. Read together, they give a clearer answer than either does alone. Both address vasomotor and sleep symptoms related to menopause specifically, not every complaint attributed to “low hormones.”
Where the Evidence Is Strong: Hot Flashes, Night Sweats, and VMS-Linked Sleep
This is HRT’s core, best-supported use under both ACOG and ACP guidance.
Hot Flashes and Night Sweats
Systemic hormone therapy is the strongly recommended, first-line treatment for vasomotor symptoms in eligible patients. In the evidence base, estrogen (paired with a progestogen when needed) outperforms nonhormonal options for this cluster. For patients who cannot use hormone therapy or choose not to, ACP’s stepwise approach offers SNRIs next, followed by SSRIs, gabapentin, or neurokinin receptor antagonists.
VMS-Related Sleep Disturbance
The key nuance is this: ACOG’s strong recommendation applies to sleep disturbance caused by vasomotor symptoms, not sleep problems in general. The guideline states plainly that evidence is insufficient to determine whether hormone therapy consistently improves sleep in women without VMS. A sleep complaint therefore needs to be traced to its cause before HRT can reasonably be expected to help.
Where the Evidence Is Conditional or Insufficient: Mood and Non-VMS Sleep
This is where much consumer content oversimplifies by implying HRT broadly treats mood and sleep.
Depressive Symptoms Without Vasomotor Symptoms
ACOG states that the evidence is insufficient to recommend for or against estrogen-progestogen or estrogen-only therapy for menopause-related depressive symptoms. Patients who meet diagnostic criteria for major depressive disorder should be treated according to established depression-management guidelines, with HRT not serving as a substitute.
When depressive symptoms occur alongside prominent VMS, relief from hot flashes and night sweats may support mood indirectly. That is different from treating depression directly.
Sleep Disturbance Without a Vasomotor Cause
Sleep complaints unrelated to hot flashes or night sweats fall outside the strong recommendation. A careful evaluation of sleep patterns and symptom timing matters more than assuming HRT will resolve general insomnia.
Vaginal and Urinary Symptoms: Two Separate Decision Points
Systemic HRT and local vaginal estrogen are different treatments chosen for different purposes. They are not interchangeable versions of one therapy.
Systemic Hormone Therapy
Systemic therapy comes as a pill, patch, ring, gel, cream, or spray and delivers hormones throughout the body. It can address vasomotor and sleep symptoms and, secondarily, vaginal symptoms. It is typically chosen when multiple clusters appear together, such as hot flashes plus vaginal dryness.
Local Vaginal Estrogen
Low-dose vaginal estrogen (cream, tablet, or ring) usually contains less estrogen than systemic therapy and is used specifically for vaginal and urinary symptoms. It is often appropriate even for patients who are not candidates for systemic therapy or do not need it. This is a separate clinical decision, not a “lighter version” of the same choice. The symptom profile, rather than preference alone, should determine the route.
Libido and the Testosterone Question
Some wellness brands market testosterone to women as a general “low-T” fix. Clinical reality is narrower. Testosterone remains off-label for women in the U.S., and specialty guidelines recognize one evidence-based indication: hypoactive sexual desire disorder (HSDD) in postmenopausal women.
Testosterone is not an evidence-supported treatment for fatigue, brain fog, or low energy in women. Libido concerns should first be evaluated for underlying causes, including vaginal symptoms, mood, relationship factors, or HSDD itself.
Formulation Matters: Progestogen Needs and the Bioidentical Question
Patients with a uterus need a progestogen alongside estrogen to protect the uterine lining. Estrogen-only therapy is reserved for those who have had a hysterectomy.
FDA-approved bioidentical options, such as estradiol patches and micronized progesterone, differ from compounded bioidentical hormone therapy (cBHT). ACOG’s November 2023 Clinical Consensus No. 6 advises that cBHT should not be prescribed routinely when FDA-approved formulations exist, citing dosing variability exceeding ±20%, contamination, sterility concerns, and unreported adverse events. “Bioidentical” does not mean “compounded.”
The FDA Black-Box Warning Removal: What Changed and What Didn’t
In November 2025, the FDA announced the removal of certain black-box warnings from HRT labeling, finalized for six branded products on February 12, 2026. The removed language referenced cardiovascular disease, breast cancer, and probable dementia.
What did not change: the endometrial-cancer warning remains for estrogen-only systemic products. The update reflects a revised approach to risk communication, not a finding that HRT is low-risk for everyone. It supports more individualized prescribing rather than a blanket endorsement.
Nonhormonal Options in Context
The 2026 guidelines highlight fezolinetant, FDA-approved in 2023, and elinzanetant, approved in 2025, as alternatives for patients who cannot or prefer not to use hormones. Hormone therapy held the largest share of the menopause-treatment market in 2025 (46.8%), while nonhormonal therapy is the fastest-growing segment. That pattern points to more individualized decisions, not a decline in hormone therapy’s relevance. These options apply to vasomotor symptoms, not to the vaginal, mood, or libido concerns above.
The Window of Opportunity: Why Timing Drives Eligibility
Both ACOG and ACP anchor on the same point: HRT’s benefit-risk ratio is most favorable before age 60 or within 10 years of the final menstrual period. Two patients with identical hot flash frequency can have very different risk profiles depending on time since menopause. Eligibility is a clinical determination involving age, menopausal timing, and personal and family history, not simply symptom severity.
Bringing It Together: A Symptom-by-Evidence Summary
- Strongly recommended: hot flashes, night sweats, VMS-related sleep disturbance
- Insufficient evidence: depressive symptoms without VMS, non-vasomotor sleep problems
- Route-dependent: vaginal and urinary symptoms (systemic vs. local)
- Narrowly indicated: testosterone for HSDD in postmenopausal women
Formulation and timing sit beneath every one of these decisions, which is why personalized evaluation matters.
Conclusion: Precision Over Blanket Claims
The 2026 guidelines support HRT strongly for some symptoms and conditionally or not at all for others. At Red Mountain, hormone optimization is treated as a tool for restoring how the body functions, used within a structured, clinically guided plan rather than sold as a universal fix. Women navigating perimenopause or menopause deserve a provider who can explain which symptoms the evidence supports and which call for a different approach.
Is HRT the Right Fit for Your Symptoms?
Mapping symptoms to the evidence, confirming eligibility within the window of opportunity, and choosing the right formulation and route are what a clinical consultation is designed to sort through. Online symptom lists cannot do that work. If these distinctions sound familiar, a consult with Red Mountain’s in-person providers is usually the next step toward clarity, without any commitment.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.
